Therapy of persistent human papillomavirus disease with two different interferon species.
Consensus interferon and interferon alfa-2a were used to treat patients with persistent human papillomavirus disease. Thirty-one patients were treated with either consensus interferon or a placebo (25 received active drug and 6 received placebo), and 24 patients were treated with interferon alfa-2a. Of the 25 patients who received consensus interferon, 19 (76%) showed either complete or partial clearing of condyloma 10 and 16 weeks after initiation of therapy; in 22 of the 24 patients (91%) who received interferon alfa-2a, clearing was demonstrated after a similar time period. Thirty of 34 patients who had no response or a partial response requested additional therapy, and 20 of these patients treated with adjunctive therapy had a complete response. The results of this study support the efficacy of both interferons in the treatment of overt condyloma acuminatum and suggest that interferon enhances subsequent adjunctive therapy.
Gall
S A
SA
Department of Obstetrics and Gynecology, University of Louisville School of Medicine, KY 40292.
Constantine
L
L
Koukol
D
D
D000293:Adolescent; D000328:Adult; D004352:Drug Resistance, Microbial; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D027383:Papillomaviridae; D011994:Recombinant Proteins; D014412:Tumor Virus Infections / Q000188:drug therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D007372:Interferons